TENX
vs
S&P 500
TENX
S&P 500
Over the past 12 months, TENX has significantly outperformed S&P 500, delivering a return of +139% compared to the S&P 500's +14% growth.
Stocks Performance
TENX vs S&P 500
Performance Gap
TENX vs S&P 500
Performance By Year
TENX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Tenax Therapeutics Inc
Glance View
Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The company is headquartered in Morrisville, North Carolina and currently employs 8 full-time employees. The firm's products include TNX-103 (oral levosimendan) and TNX-201 (oral enteric coated imatinib). The firm's lead product, Levosimendan, is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. TNX-201 is for the treatment of pulmonary arterial hypertension (PAH), which is a fatal orphan disease. The firm has completed Phase II clinical trial of levosimendan in North America for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).